Involvement of Rho-kinase in prostaglandin F2α-stimulated interleukin-6 synthesis via p38 mitogen-activated protein kinase in osteoblasts

Molecular and Cellular Endocrinology

Volumn 291, Issue 1-2, 2008, Pages 27-32

  Minamitani, Chiho ^a,b   Otsuka, Takanobu ^a   Takai, Shinji ^b   Matsushima Nishiwaki, Rie ^b   Adachi, Seiji ^b   Hanai, Yoshiteru ^b,c   Mizutani, Jun ^a   Tokuda, Haruhiko ^b,c   Kozawa, Osamu ^b  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

IL 6; MAP kinase; Osteoblast; PGF2 ; Rho kinase

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BIRB 0796; FASUDIL; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MYOSIN PHOSPHATASE TARGETING SUBUNIT 1; PROSTAGLANDIN F2 ALPHA; RHO KINASE;

ANIMAL CELL; ARTICLE; CELL STRAIN; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; MOUSE; NEWBORN; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN FUNCTION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; 3T3 CELLS; ANIMALS; DINOPROST; ENZYME INHIBITORS; INTERLEUKIN-6; MICE; MYOSIN-LIGHT-CHAIN KINASE; OSTEOBLASTS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RHO-ASSOCIATED KINASES;

EID: 48349116048     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.05.011     Document Type: Article

References (32)

1. Akira S., Taga T., and Kishimoto T. Interleukin-6 in biology and medicine. Adv. Immunol. 54 (1993) 1-78
2. Bain J., Plater L., Matt E., Shpiro N., Hastie J., McLauchlan H., Klevernic I., Arthur S., Alessi D., and Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408 (2007) 297-315
3. Bennett B.L., Sasaki D.T., Murray B.W., O'Leary E.C., Sakata S.T., Xu W., Leisten J.C., Motiwala A., Pierce S., Satoh Y., Bhagwat S.S., Manning A.M., and Anderson D.W. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal Kinase. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 13681-13686
4. Cuenda A., Rouse J., Doza Y.N., Meier R., Cohen P., Gallagher T.F., Young P.R., and Lee J.C. SB203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 364 (1995) 229-233
5. Davies S., Reddy H., Caivano M., and Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351 (2000) 95-105
6. δ isoforms. J. Biol. Chem. 276 (2001) 29072-29078
7. Fukata Y., Amano M., and Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol. Sci. 22 (2001) 32-39
8. Godl K., Wissing J., Kurtenbach A., Habenberger P., Blencke S., Gutbrod H., Salassidis K., Stein-Gerlach M., Missio A., Cotton M., and Daub H. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 15434-15439
9. Harmey D., Stenbeck G., Nobes C.D., Lax A.J., and Grigoriadis A.E. Regulation of osteoblast differentiation by Pasteurellamultocida toxin (PMT): a role for Rho GTPase in bone formation. J. Bone Miner. Res. 19 (2004) 661-670
10. Helle M., Brakenhoff J.P.J., DeGroot E.R., and Aarden L.A. Interleukin 6 is involved in interleukin 1-induced activities. Eur. J. Immunol. 18 (1998) 957-959
11. Heymann D., and Rousselle A.V. gp130 Cytokine family and bone cells. Cytokine 12 (2000) 1455-1468
12. Ishimi Y., Miyaura C., Jin C.H., Akatsu T., Abe F., Nakamura Y., Yamaguchi Y., Yoshiki S., Matsuda T., Hirano T., Kishimoto T., and Suda T. IL-6 is produced by osteoblasts and induces bone resorption. J. Immunol. 145 (1990) 3297-3303
13. Ito M., Nakano T., Erdodi F., and Hartshorne D.J. Myosin phosphatase: structure, regulation and function. Mol. Cell. Biochem. 259 (2004) 197-209
14. 2 in osteoblast-like cells. Exp. Cell Res. 198 (1992) 130-134
15. 2α-activates phospholipase D independently from activation of protein kinase C in osteoblast-like cells. J. Cell. Biochem. 55 (1994) 373-379
16. 2α stimulates interleukin-6 via activation of PKC in osteoblast-like cells. Am. J. Physiol. 272 (1997) E208-E211
17. Kwan Tat S., Padrines M., Theoleyre S., Heymann D., and Fortun Y. IL-6, RANKL, TNF-α/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev. 15 (2004) 49-60
18. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
19. Littlewood A.J., Russil J., Harvey G.R., Hughes D.E., Russel R.G.G., and Gowen M. The modulation of the expression of IL-6 and its receptor in human osteoblasts in vitro. Endocrinology 129 (1991) 1513-1520
20. Louis C., and Einhorn A.T. In: Kleerekoper M., and Lane N. (Eds). Fracture Healing: The Biology of Bone Repair and Regeneration in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. sixth ed. (2006), The American Society for Bone and Mineral Research, USA 42-48
21. 2α-induced phosphoinositidehydrolyeis in osteoblast-like cells. Biochem. Biophys. Res. Commun. 171 (1990) 1229-1235
22. Nijweide P.J., Burger E.H., and Feyen J.H.M. Cells of bone: proliferation, differentiation, and hormonal regulation. Physiol. Rev. 86 (1986) 855-886
23. Pilbeam C.C., Harrison J.R., and Raisz L.G. Prostaglandins and bone metabolism. In: Raisz L.G., and Rodan G.A. (Eds). Principles of Bone Biology (1996), Academic Press, San Diego, USA 715-728
24. Riento K., and Ridley A.J. Rocks: multifunctional kinases in cell behaviour. Nat. Rev. Mol. Cell Biol. 4 (2003) 446-456
25. Roodman G.D. Interleukin-6: an osteotropic factor?. J. Bone Miner. Res. 7 (1992) 475-478
26. Sarkar A., Duncan M., Hart J., Hertlein E., Guttridge D.C., and Wewers M.D. ASC directs NF-κB activation by regulating receptor interacting protein-2 (RIP2) caspase-1 interactions. J. Immunol. 176 (2006) 4979-4986
27. Shimokawa H., and Rashid M. Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol. Sci. 28 (2007) 296-302
28. Sudo H., Kodama H., Amagai Y., Yamamoto S., and Kasai S. In vitro differentiation and calcification in a new clonalosteogenic cell line derived from newborn mouse calvaria. J. Cell Biol. 96 (1983) 191-198
29. 2α-induced interleukin-6 synthesis in osteoblasts. Cell. Signal. 11 (1999) 325-330
30. 2α-induced VEGF synthesis via up-regulating SAPK/JNK activation in osteoblasts. J. Cell Biochem. 100 (2007) 1146-1153
31. Widmann C., Gibson S., Jarpe M.B., and Johnson G.L. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol. Rev. 79 (1999) 143-180
32. Windischhofer W., Zach D., Fauler G., Raspotnig G., Kofeler H., and Leis H.J. Involvement of Rho and p38 MAPK in endothelin-1-induced expression of PGHS-2 mRNA in osteoblast-like cells. J. Bone Miner. Res. 17 (2002) 1774-1784